February 6, 2019

Towards the Early Diagnosis of Alzheimer’s Disease: A New Paradigm for Clinical Benefit

Hybrid 2021 European College of Neuropsychopharmacology (ECNP) Annual Meeting

An Overview of the Current Burden of Alzheimer’s Disease

Christine von Arnim, MD, provides a brief overview of AD, including the economic burden, mechanism of disease, and risk factors.

Key Learning Objectives from Biogen’s ECNP 2021 Symposium:

  • Provide an understanding of the cognitive, functional, and behavioral symptoms of early-stage AD and the range of tools used to assess the clinical syndrome, with a focus on neuropsychiatric measures
  • Outline the utility of imaging and fluid biomarkers as a complement to clinical assessment for enhancing the early detection and diagnosis of AD
  • Highlight the need for a paradigm shift in AD healthcare across Europe, with best practice strategies to optimize detection, diagnosis, and management

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.